148 related articles for article (PubMed ID: 34117193)
1. Oncostatin-M Does Not Predict Treatment Response in Inflammatory Bowel Disease in a Pediatric Cohort.
Ezirike Ladipo J; He Z; Chikwava K; Robbins K; Beri J; Molle-Rios Z
J Pediatr Gastroenterol Nutr; 2021 Sep; 73(3):352-357. PubMed ID: 34117193
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.
West NR; Hegazy AN; Owens BMJ; Bullers SJ; Linggi B; Buonocore S; Coccia M; Görtz D; This S; Stockenhuber K; Pott J; Friedrich M; Ryzhakov G; Baribaud F; Brodmerkel C; Cieluch C; Rahman N; Müller-Newen G; Owens RJ; Kühl AA; Maloy KJ; Plevy SE; ; Keshav S; Travis SPL; Powrie F
Nat Med; 2017 May; 23(5):579-589. PubMed ID: 28368383
[TBL] [Abstract][Full Text] [Related]
3. Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.
Verstockt S; Verstockt B; Machiels K; Vancamelbeke M; Ferrante M; Cleynen I; De Hertogh G; Vermeire S
Inflamm Bowel Dis; 2021 Oct; 27(10):1564-1575. PubMed ID: 33624092
[TBL] [Abstract][Full Text] [Related]
4. High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonists.
Guo A; Ross C; Chande N; Gregor J; Ponich T; Khanna R; Sey M; Beaton M; Yan B; Kim RB; Wilson A
Sci Rep; 2022 Jan; 12(1):1185. PubMed ID: 35075155
[TBL] [Abstract][Full Text] [Related]
5. Oncostatin M Induces a Pro-inflammatory Phenotype in Intestinal Subepithelial Myofibroblasts.
Kokkotis G; Filidou E; Tarapatzi G; Spathakis M; Kandilogiannakis L; Dovrolis N; Arvanitidis K; Drygiannakis I; Valatas V; Vradelis S; Manolopoulos VG; Paspaliaris V; Kolios G; Bamias G
Inflamm Bowel Dis; 2024 May; ():. PubMed ID: 38717842
[TBL] [Abstract][Full Text] [Related]
6. Feiyangchangweiyan capsule protects against ulcerative colitis in mice by modulating the OSM/OSMR pathway and improving gut microbiota.
Li Y; Chen F; Xie Y; Yang Q; Luo H; Jia P; Shi Z; Wang S; Zheng X
Phytomedicine; 2021 Jan; 80():153372. PubMed ID: 33113505
[TBL] [Abstract][Full Text] [Related]
7. Oncostatin M pathway plays a major role in the renal acute phase response.
Luyckx VA; Cairo LV; Compston CA; Phan WL; Mueller TF
Am J Physiol Renal Physiol; 2009 Apr; 296(4):F875-83. PubMed ID: 19158344
[TBL] [Abstract][Full Text] [Related]
8. Anti-oncostatin M antibody inhibits the pro-malignant effects of oncostatin M receptor overexpression in squamous cell carcinoma.
Kucia-Tran JA; Tulkki V; Scarpini CG; Smith S; Wallberg M; Paez-Ribes M; Araujo AM; Botthoff J; Feeney M; Hughes K; Caffarel MM; Coleman N
J Pathol; 2018 Mar; 244(3):283-295. PubMed ID: 29205362
[TBL] [Abstract][Full Text] [Related]
9. Loss of Oncostatin M Signaling in Adipocytes Induces Insulin Resistance and Adipose Tissue Inflammation in Vivo.
Elks CM; Zhao P; Grant RW; Hang H; Bailey JL; Burk DH; McNulty MA; Mynatt RL; Stephens JM
J Biol Chem; 2016 Aug; 291(33):17066-76. PubMed ID: 27325693
[TBL] [Abstract][Full Text] [Related]
10. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
[TBL] [Abstract][Full Text] [Related]
11. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R
Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648
[TBL] [Abstract][Full Text] [Related]
13. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice.
Adrian-Segarra JM; Sreenivasan K; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 Dec; 293(52):20181-20199. PubMed ID: 30373773
[TBL] [Abstract][Full Text] [Related]
14. Oncostatin M suppresses oestrogen receptor-α expression and is associated with poor outcome in human breast cancer.
West NR; Murphy LC; Watson PH
Endocr Relat Cancer; 2012 Apr; 19(2):181-95. PubMed ID: 22267707
[TBL] [Abstract][Full Text] [Related]
15. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
16. Oncostatin M mediates STAT3-dependent intestinal epithelial restitution via increased cell proliferation, decreased apoptosis and upregulation of SERPIN family members.
Beigel F; Friedrich M; Probst C; Sotlar K; Göke B; Diegelmann J; Brand S
PLoS One; 2014; 9(4):e93498. PubMed ID: 24710357
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the oncostatin M receptor in cervical squamous cell carcinoma cells is associated with a pro-angiogenic phenotype and increased cell motility and invasiveness.
Winder DM; Chattopadhyay A; Muralidhar B; Bauer J; English WR; Zhang X; Karagavriilidou K; Roberts I; Pett MR; Murphy G; Coleman N
J Pathol; 2011 Nov; 225(3):448-62. PubMed ID: 21952923
[TBL] [Abstract][Full Text] [Related]
18. Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay.
Cao Y; Dai Y; Zhang L; Wang D; Yu Q; Hu W; Wang X; Yu P; Ping Y; Sun T; Sang Y; Liu Z; Chen Y; Tao Z
Clin Biochem; 2022 Feb; 100():35-41. PubMed ID: 34843732
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M and its receptors mRNA regulation in bovine granulosa and luteal cells.
Martins KR; Haas CS; Ferst JG; Rovani MT; Goetten ALF; Duggavathi R; Bordignon V; Portela VVM; Ferreira R; Gonçalves PBD; Gasperin BG; Lucia T
Theriogenology; 2019 Feb; 125():324-330. PubMed ID: 30504073
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.
Geethadevi A; Nair A; Parashar D; Ku Z; Xiong W; Deng H; Li Y; George J; McAllister DM; Sun Y; Kadamberi IP; Gupta P; Dwinell MB; Bradley WH; Rader JS; Rui H; Schwabe RF; Zhang N; Pradeep S; An Z; Chaluvally-Raghavan P
Cancer Res; 2021 Oct; 81(20):5336-5352. PubMed ID: 34380633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
